AR117191A1 - Composiciones inmunogénicas - Google Patents

Composiciones inmunogénicas

Info

Publication number
AR117191A1
AR117191A1 ARP190103212A ARP190103212A AR117191A1 AR 117191 A1 AR117191 A1 AR 117191A1 AR P190103212 A ARP190103212 A AR P190103212A AR P190103212 A ARP190103212 A AR P190103212A AR 117191 A1 AR117191 A1 AR 117191A1
Authority
AR
Argentina
Prior art keywords
present
immunogenic compositions
vme
patient
composition
Prior art date
Application number
ARP190103212A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR117191A1 publication Critical patent/AR117191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente proporciona una composición inmunogénica que comprende VME y (a) antígeno acelular de la tos ferina, (b) un toxoide tetánico y (c) un toxoide diftérico, en la que las VME se obtienen de Bordetella pertussis. La presente también proporciona composiciones para su uso en un procedimiento de aumento de la respuesta inmunitaria en un paciente, que comprende la etapa de administrar al paciente una composición de la presente.
ARP190103212A 2018-11-06 2019-11-04 Composiciones inmunogénicas AR117191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18204691 2018-11-06

Publications (1)

Publication Number Publication Date
AR117191A1 true AR117191A1 (es) 2021-07-21

Family

ID=64456746

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103212A AR117191A1 (es) 2018-11-06 2019-11-04 Composiciones inmunogénicas

Country Status (14)

Country Link
US (1) US20230201325A1 (es)
EP (1) EP3876982A1 (es)
JP (1) JP7469302B2 (es)
KR (1) KR20210090646A (es)
CN (1) CN112996538A (es)
AR (1) AR117191A1 (es)
AU (1) AU2019376832B2 (es)
BR (1) BR112021007668A2 (es)
CA (1) CA3117867A1 (es)
EA (1) EA202190914A1 (es)
IL (1) IL282753A (es)
MX (1) MX2021005303A (es)
SG (1) SG11202103389WA (es)
WO (1) WO2020094580A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123063A2 (en) 2020-12-11 2022-06-16 Glaxosmithkline Biologicals Sa Hyper-blebbing bacteria
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
ES2078258T3 (es) 1989-04-28 1995-12-16 Sclavo Spa Mutantes de toxina pertussica, cepas de bordetella capaces de producir tales mutantes y su uso en el desarrollo de vacunas antipertussicas.
EP2266604A3 (en) 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
PT1150918E (pt) 1999-02-03 2005-01-31 Biosante Pharmaceuticals Inc Metodo de fabrico de particulas terapeuticas de fosfato de calcio
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
CA2393298C (en) 1999-12-02 2011-02-01 Chiron Corporation Compositions and methods for stabilizing biological molecules upon lyophilization
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
EP2255826B1 (en) * 2002-08-02 2016-04-13 GlaxoSmithKline Biologicals S.A. Neisserial vaccine compositions comprising a combination of antigens
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
EP2802646B1 (en) * 2011-12-21 2017-05-10 Bionet-Asia Co. Ltd Modified bordetella pertussis strains
ES2848048T3 (es) * 2012-10-03 2021-08-05 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas
ES2597832T3 (es) 2013-03-08 2017-01-23 Janssen Vaccines & Prevention B.V. Vacuna acelular contra la tosferina
AR090538A1 (es) 2013-03-27 2014-11-19 Consejo Nac Invest Cient Tec Vacuna para la prevencion de infecciones con bordetella
BE1022008B1 (fr) 2013-08-05 2016-02-03 Glaxosmithkline Biologicals S.A. Compositions immunogenes combinees

Also Published As

Publication number Publication date
AU2019376832A1 (en) 2021-05-13
IL282753A (en) 2021-06-30
JP2022506347A (ja) 2022-01-17
WO2020094580A1 (en) 2020-05-14
CN112996538A (zh) 2021-06-18
CA3117867A1 (en) 2020-05-14
MX2021005303A (es) 2021-07-07
KR20210090646A (ko) 2021-07-20
AU2019376832B2 (en) 2024-01-25
EP3876982A1 (en) 2021-09-15
SG11202103389WA (en) 2021-05-28
BR112021007668A2 (pt) 2021-07-27
JP7469302B2 (ja) 2024-04-16
US20230201325A1 (en) 2023-06-29
EA202190914A1 (ru) 2021-08-03

Similar Documents

Publication Publication Date Title
CY1118521T1 (el) Συνθεση εμβολιου και μεθοδος χρησης αυτου
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
AR092896A1 (es) Composiciones inmunogenicas
AR053711A1 (es) Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion
ECSP22072586A (es) VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
BR112012004698A2 (pt) métodos de redução de atividade virucida em composições de pcv-2 e composições de pcv-2 com uma imonugenicidade aprimorada.
AR090294A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
CO6321162A2 (es) Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante
BR112013017171A2 (pt) vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
AR117191A1 (es) Composiciones inmunogénicas
BR112015005056A2 (pt) vacinas de combinação com sorogrupo b meningococcus e d/t/p
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
BR112015021523A2 (pt) composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
MX2023012530A (es) Composición y metodos de vacuna adyuvada.
PE20211648A1 (es) Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
CO6341568A2 (es) Composicion inmunologica
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
BR112022003698A2 (pt) Método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêutica
AR088908A1 (es) Vacuna
CL2022000086A1 (es) Vacunas contra ehrlichia y composiciones inmunogénicas